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To improve the efficacy of immunotherapy for cancer and autoimmune diseases, recent
ongoing and completed clinical trials have focused on specific targets to redirect the
immune network toward eradicating a variety of tumors and ameliorating the self-
destructive process. In a previous review, both systemic immunomodulators and mon-
oclonal antibodies (mAbs), anti-CTLA-4, and anti-CD52, were discussed regarding thera-
peutics and autoimmune sequelae, as well as predisposing factors known to exacerbate
immune-related adverse events (irAEs). This review will focus on immune-checkpoint
inhibitors, and the data from most clinical trials involve blockade with anti-CTLA-4 such as
ipilimumab. However, despite the mild to severe irAEs observed with ipilimumab in ~60%
of patients, overall survival (OS) averaged ~22–25% at 3–5 years.To boost OS, other mAbs
targeting programed death-1 and its ligand are undergoing clinical trials as monotherapy or
dual therapy with anti-CTLA-4.Therapeutic combinations may generate different spectrum
of opportunistic autoimmune disorders.To simulate clinical scenarios, we have applied reg-
ulatory T cell perturbation to murine models combined to examine the balance between
thyroid autoimmunity and tumor-specific immunity.
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INTRODUCTION
In recent decades, cancer therapy has focused on amplifying the
immune system to bolster the host’s anti-tumor response. Utiliz-
ing systemic immunomodulators, monoclonal antibodies (mAbs),
and stem cell transplantation, progress has been rapid in prolong-
ing survival. However, targeted immunotherapy has come with
a price; altered immunoregulation provoking immune dysfunc-
tion has opened the door to opportunistic autoimmune disorders.
Previously, both systemic immunomodulators and mAbs, anti-
CTLA-4 and anti-CD52, were discussed in terms of therapeutic
usage, autoimmune sequelae, and important predisposing fac-
tors, e.g., HLA class II genes and gender predilection, known
to influence immune-related adverse events (irAEs) (1). Simi-
lar and additional immunotherapeutic modalities associated with
autoimmunity, particularly thyroid dysfunction, were likewise
highlighted by others (2, 3). In addition to CTLA-4, a num-
ber of immune-checkpoints are also being targeted in cancer
immunotherapy. Thus far, the most information has come from
longer and larger clinical trials with anti-CTLA-4 (ipilimumab
and tremelimumab), accompanied by mild to severe irAEs (4–6).
In early trials, it was hoped that irAEs could serve as a predic-
tor of improving anti-CTLA-4 immunotherapy (7, 8). However,
analysis of 139 metastatic melanoma patients given ipilimumab
revealed that the frequency of irAEs after a 2–4 year follow-up
was 81% with a total response rate of 17% (23 of 139) (7); of
the 86 patients with irAEs, 74% (64 of 86) showed no objective
improvement (1).
Thus, targeting CTLA-4, a T cell regulatory molecule, impacts
on its two primary functions in the immune network: (1) Its
upregulation during a T cell-mediated response serves as a negative
regulator by engaging the B7 family costimulatory molecules on
antigen-presenting cells with higher avidity than CD28 (9); and (2)
Its constitutive expression on regulatory T cells (Tregs) is critical
to the Foxp3 function in suppressing autoreactive T cell activation
(10, 11). ctla4−/− mice develop severe multiorgan autoimmu-
nity, indicative of deficiency in both these functions (12, 13).
When humanized CTLA-4 mAbs were first used to treat advanced
melanoma a decade ago, the major goal was to interfere with
the negative signaling of an ongoing anti-tumor response dis-
cernible in many patients (4, 6). However, since a key role of
CTLA-4 is to enable Treg suppression of autoreactive T cell acti-
vation at the costimulatory level of DC (10, 11), it was no surprise
that opportunistic autoimmune disorders surfaced as prominent
irAEs from CTLA-4 blockade. The variety stems from the ever-
present autoantigens and autoreactive T cells unleashed from self
tolerance regulation (1). For example, in our tolerance induction
study in murine experimental autoimmune thyroiditis (EAT), a
model for the prevalent Hashimoto’s thyroiditis (14), co-injection
of anti-CTLA-4 with the autoantigen, thyroglobulin (Tg), inter-
fered with activation of naturally existing CD4+CD25+Foxp3+
Tregs (nTregs); the mice developed thyroiditis, mimicking a major
clinical autoimmune sequela (15).
Using revised assessment criteria including overall survival
(OS) in phase II/III trials to take into account the longer sur-
vival kinetics for ipilimumab (16), recent compilation of ipili-
mumab phase I/II trial results showed a range of 12–36% OS
at 3–5 years, with variables including the dose, patient num-
ber, prior, or adjunct treatment (4). Pooling phase II/III trials
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showed irAEs approximating 60% with less severe grade 3–4 in
the phase III trials, likely due to earlier recognition and man-
agement of autoimmune sequelae (4, 17). While the percentages
of irAEs varied, most included skin rashes, colitis, thyroid dys-
function, hypophysitis, hepatitis, and pancreatitis (4, 17), as also
reported in western Europe (5). Treatment-related deaths con-
tinued to occur and severe morbidity required stringent life-long
treatment and hormonal supplementation (4, 5). The second mAb,
tremelimumab, likewise underwent phase I/II trials [see Ref. (1)]
and phase III trials with similar irAEs but less durable OS than
with ipilimumab; in fact, survival was not much longer than
after standard chemotherapy with temozolomide or dacarbazine
(6). To boost OS, mAbs that blockade the function of another
immune-checkpoint, programed death-1 (PD-1), or its ligand
(PD-L1), have been undergoing clinical trials as monotherapy or
dual therapy with anti-CTLA-4.
MODELS TO PROBE THE BALANCE BETWEEN
AUTOIMMUNITY AND TUMOR IMMUNITY UPON Treg
PERTURBATION
The high percentages of irAEs from anti-CTLA-4 therapy clearly
show that maintenance of Treg function and self tolerance con-
stitutes a premier CTLA-4 function. Autoimmune thyroid disease,
including Hashimoto’s thyroiditis and Graves’ disease, represents
the most prevalent autoimmune condition (18), and CTLA-4
blockade has joined other systemic immunomodulators [e.g.,
interferon-α, -β, interleukin (IL)-2] and leukocyte-target agents
(e.g., anti-CD52) in triggering thyroid dysfunction (1, 3, 19, 20).
As EAT has long served as a model to study Treg function in self tol-
erance to mouse Tg (14, 21, 22), we developed in recent years four
murine models combining EAT and breast cancer vaccine proto-
cols under Treg perturbation and MHC class II gene influence,
using autoimmune thyroiditis as a sequela indicator (23).
The first three utilized well-established tumor models in wild
type mice or mice transgenic for Her-2/neu breast cancer anti-
gen, which harbor class II-linked, EAT-resistant haplotype (H2d
or H2b). In the first model, we induced EAT concurrently with
anti-tumor immunity in wild type mice at the time of Treg deple-
tion with mAb to CD25 (24). Treg depletion enhanced tumor
regression and thyroiditis. Immune responses to neu and mouse
Tg were greater than control groups given tumor or Tg alone, indi-
cating that ongoing tumor regression and autoimmune response
provided additional mutual stimuli. In the second model, we used
rat neu-transgenic mice, which required both Treg depletion and
neu DNA vaccination to develop resistance to tumor challenge
and spontaneous tumorigenesis (25). Mutual stimulation during
responses to neu and mouse Tg was again observed. In tumor-
regressing mice, there were significant increases in interferon-
γ-producing T cells and greater thyroid destruction even in the
EAT-resistant strain. Lastly, in the third model, we introduced
the HLA-DR3 transgene, an EAT-susceptible allele (26), and an
Her-2 transgene into EAT-resistant H2Ab mice to determine if
anti-tumor response was independent of EAT susceptibility. (Ab-
Her-2xDR3)F1 mice expressed both Ab and DR3 and were tolerant
to both Tg and Her-2 (27). After Treg depletion followed by Her-
2 DNA and mouse Tg injections, tumor rejection was similar in
Her-2 transgenic mice expressing either Ab or Ab/DR3, but thy-
roiditis was augmented only in (Ab/DR3)F1 mice, showing that
Her-2 immunity, unlike autoimmunity, was independent of DR3
expression.
In the fourth combined model, we used an EAT-susceptible
CBA/J (H2k) haplotype with demonstrated antigen-specific nTreg-
mediated tolerance. Depleting pre-existing nTregs markedly
enhanced thyroiditis development with soluble mouse Tg even
without adjuvant (15). Control mice with nTregs, which had
been activated/expanded after exposure to mouse Tg by either
injection or physiologic release (via thyroid-stimulating hormone
infusion in an osmotic pump), withstood EAT induction with
mouse Tg plus adjuvant (22, 28). In contrast, nTreg-depleted mice
were incapable of establishing this strong and long-lasting tol-
erance (14, 15, 22). For the cancer portion, CBA/J tumor was
derived from a spontaneous mammary adenocarcinoma line, and
resistance to lethal challenge was instilled by prior Treg deple-
tion and vaccination with irradiated tumor cells (23). To simulate
patients with MHC class II-associated predisposition to autoim-
munity and subjected to immune targeting, mouse Tg was also
given. Treg depletion not only augmented tumor immunity but
also thyroidal infiltration (29). Furthermore, to simulate the sce-
nario in some cancer patients with pre-existing autoimmunity
and given immunotherapy, mice were pretreated with mouse
Tg + low doses of IL-1 to establish a subclinical, mild thyroidi-
tis condition. Treg depletion, tumor vaccination, and mouse Tg
injections then followed. While anti-tumor immunity remained
unchanged, thyroiditis was exacerbated (29). Thus, this recent
model takes into account genetically predisposed patients who
have no underlying thyroid dysfunction or have pre-existing,
undiagnosed disease.
TARGETING CTLA-4 LED TO UNUSUAL SPECTRUM OF
AUTOIMMUNE SEQUELAE
In murine EAT, tolerance induction with the known autoantigen,
mouse Tg, and its blockade of nTreg activation by anti-CTLA-
4 to allow thyroiditis development can be followed with timed
co-administration (15). However, in cancer patients, there are
multiple self antigens for which the maintenance mechanisms
of self tolerance can be disrupted with anti-CTLA-4 therapy at
varying doses and intervals, resulting in unpredictable manifesta-
tions of 20–60% of irAEs with grade 1–4 severity. In addition
to advanced melanoma, both ipilimumab and tremelimumab
have been used to treat other solid tumors and hematologic
cancers and the frequent irAEs have included dermatitis, ente-
rocolitis, hepatitis, thyroid dysfunction, and hypophysitis with
widespread endocrinopathies, irrespective of cancer types (3–6,
19, 20). Although these autoimmune diseases are primarily organ-
specific, T cell-mediated, and with mononuclear cell infiltration of
the specific organ, plasma cells may be seen with time. Moreover,
when several organs are involved with attendant proinflammatory
cytokines, irAEs may become exacerbated and more widespread.
Thus, different irAEs often occur throughout the treatment period
and beyond.
There is agreement that the extent of severe irAEs is dose-
dependent, but OS improvement generally does not correspond
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linearly with dosage (5), nor correlates with severity of irAEs
(1, 19). Torino et al. (19) undertook an in-depth analysis of
endocrine dysfunction for 21 phase I–III trials with ipilimumab
treatment of melanoma and several other solid tumors. The
primary emphasis was on hypophysitis of grades 3–4, but the
involvement of other endocrine dysfunctions (hypothyroidism,
adrenal insufficiency) and other common irAEs (e.g., diarrhea,
colitis/enterocolitis, dermatitis, hepatitis, and arthritis) was also
included. A more recent report by some of the same authors,
Corsello et al. (20), extended the analysis to 28 trials, subcatego-
rizing classifiable endocrine disorders and other common irAEs,
which may or may not be autoimmune in origin. As mentioned
above, since irAEs generally involved up to 60% of patients, at 2–
3× the OS, a direct correlation of OS with irAE would be difficult
at this time (4).
As discussed earlier (1), while the increase in thyroid dysfunc-
tion could have been anticipated, given the high prevalence in
the general population, the most unusual and distinct associa-
tion with anti-CTLA-4 therapy is autoimmune hypophysitis, with
an incidence of 3–9% in early trials far exceeding its rare occur-
rence (~1 in 0.5 million) (19, 30). Another early melanoma trial
with ipilimumab reported 17% (8 of 46) (31). The analyses of
clinical trials with ipilimumab and tremelimumab gave an aver-
age of ~4% hypophysitis, closely rivaling hypothyroidism (19,
20). While hypothyroidism is 5–6× more prevalent in females in
Caucasians (18), thus far hypophysitis from anti-CTLA-4 therapy
has occurred mostly in males, in part influenced by the ratio of
female:male of ~1:2 in melanoma patients. Other genetic (HLA,
CTLA-4 gene polymorphism, mutations) and environmental fac-
tors may also take part (1, 4, 32). The high incidence of hypophysi-
tis, its need for early corticosteroid intervention and life-long
hormonal replacement prompted the advocacy of early recogni-
tion and management, together with thyroid function tests (17,
19, 20). Searches for specific pituitary antigens for early antibody
detection to replace immunofluorescence on pituitary sections are
ongoing (33–35).
Although autoimmune sequelae (e.g., hypophysitis, thyroid
dysfunction, and hormonal imbalance) are gaining recognition,
the high incidences of colitis and dermatitis have not been inves-
tigated as to culprit antigens, which could be self, commensally
microbial, or tumor-associated. A recent survey of anti-CTLA-4
therapy in 752 melanoma patients at 19 skin centers in west-
ern Europe excluded colitis and dermatitis from the usually
observed 60% irAEs (4, 5), and concentrated on raising aware-
ness to rare yet severe toxicities, some of which may be related
to prior chemo- or radio-therapy. A total of 88 irAEs from
82 of 752 (11%) patients were tabulated, 12 with hypophysi-
tis (5). With melanoma patients, the side effects of vitiligo
and uveitis were often noted because of shared melanocyte
antigens, often aggravated by vaccination (1, 5). The 15 rarer
cases included gastric problems, ischemia and bowel perfora-
tions, fatal hepatitis, hypophysitis with brain edema, and inflam-
mation of the central nervous system. There were also res-
piratory and cardiac problems. Thus, the untoward autoim-
mune disorders are opportunistic and unpredictable, as well as
far-reaching.
SPECIFIC ANTIGENS TO BOOST TUMOR IMMUNITY AND
MONITOR Treg ACTIVITY
As seen above, the weakly immunogenic, tumor-associated anti-
gens, which can be overexpressed self, altered self, or neoantigens,
are further interwoven with unexpected pathogenic autoanti-
gens during CTLA-4 blockade. Examination of tumor infiltrates
after tremelimumab therapy revealed an increase in activated
CD8+ T cells in many melanoma patients; while not Tregs, this
non-specific increase was observed in a greater proportion of
patients than patients deriving any clinical benefit and showed no
correlation with either tumor progression or regression (36). In
phase II trials of melanoma patients with ipilimumab, a periph-
eral increase in the %CD4+ and %CD8+ activated T cells, but
not those with a Treg phenotype, was noted (37). Of interest
was the greater serologic reactivity to several melanoma anti-
gens and a cancer-testis antigen NY-ESO-1. Because NY-ESO-1
is expressed in a number of solid tumors and 30–40% of advanced
melanoma patients, it has been examined as a specific biomarker
for increased T and B cell reactivity after CTLA-4 blockade, and if
such reactivities could be associated with positive clinical out-
come (37–40). While an increase in anti-NY-ESO-1 has often
been detected, its association with positive benefit is still contro-
versial (38–40). However, it appeared that clinical benefit could
be associated with NY-ESO-1 reactivity if both antibody and
CD8+ T cells were considered in concert (10 of 13 or 77%) (39).
More such studies will be needed to determine if specific reac-
tivity to NY-ESO-1 as well as other melanoma peptides has a
predictive value. Meanwhile, to increase the efficacy of CTLA-4
blockade and detect changes in tumor-specific effector T cells,
therapeutic vaccines are being incorporated. In a large phase III
trial (41), a gp100 peptide vaccine was given with ipilimumab
(403 patients), compared to ipilimumab (137) or gp100 (136)
alone. However, there was no significant increase in OS pro-
vided by including gp100 vaccination, compared to ipilimumab
alone.
Detecting antigen-specific effector T cells is complicated by the
presence of Tregs. In the tumor microenvironment, induced Tregs
(iTregs) represent a major component of suppressor cell subsets
and, as opposed to nTregs, usually arise or are converted from
naive T cells in response to antigenic stimulus plus local TGF-
β and IL-10 production (42). Intratumoral iTregs often exist in
greater percentages than in the periphery. Although in murine
melanoma studies Fc-dependent ADCC-like depletion of Tregs
was demonstrable upon anti-CTLA treatment (43), the frequent
detection of intratumoral iTregs in the human suggests that this
kind of depletion might be an adjunct to improved clinical bene-
fit. But the challenge remains to identify whether the effect was on
tumor-specific iTregs, so as to monitor and inhibit their suppres-
sor role (44). Following therapeutic vaccination, multiple peptides
have been used to monitor iTreg activity. In one phase II trial in
renal cell cancer patients, cyclophosphamide, known to deplete
Tregs (22), was given before the IMA901 vaccine, consisting of
multiple tumor-associated peptides used to demonstrate height-
ened T cell responses (45). In another study, synthetic peptides
were used to compare the repertoire of tumor-specific iTregs
and effector T cells in colorectal carcinoma patients (46). While
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differences were noted between the two populations, the suppres-
sor activity was shown to stem from iTregs that shared the same
repertoire as effector T cells. Additional studies have made use
of class II tetramers to monitor antigen specificity. After vacci-
nation of melanoma patients with HLA-A2-restricted Melan-A
peptide, monitoring with HLA-DQ6-restricted Melan-A peptide
multimers revealed a downshift in specific Tregs with increased
effector T cell responses (47). In breast cancer patients, tetramers
from HLA-DR4-, DR7-restricted mammaglobin peptides were
used to detect iTregs in the periphery (48). After their depletion
in vitro, effector T cell responses to several mammaglobin pep-
tides increased. Thus, antigenic specificity, if known, could aid
assessment of immunotherapeutic efficacy.
PD-1 AND PD-L1 BLOCKADE TO AUGMENT TUMOR
IMMUNITY
Recent reviews have discussed in depth the phenomenon of T
cell exhaustion, where activated T cells highly expressing PD-1,
as exemplified by virus-specific CD8+ cells, exhibited exhaus-
tion phenotypes and failed to combat chronic infections (49–51).
In the tumor microenvironment, PD-1 expression was found on
impaired infiltrating lymphocytes (52) and Tregs (53). Its major
ligand, PD-L1, has been found on multiple epithelial carcino-
mas, compared to PD-L2 on lymphoid tumors associated with
its expression pattern (49–51). There is no clear consensus on
whether PD-L1 expression by tumors is associated with greater
objective response from PD-1 blockade; more specific staining
reagents have led to reports of positive association (54, 55). PD-1
is also expressed on activated B, NK, and NKT cells and is involved
in down-regulating autoimmunity. PD-1-deficient C57BL/6 mice
exhibited lupus-like arthritis and glomerulonephritis (56), and
PD-1-deficient BALB/c mice developed cardiomyopathy from an
autoantibody to cardiac troponin 1 (57). Thus, these autoim-
mune syndromes have a strong pathogenic autoantibody compo-
nent. While preclinical tumor models have shown clinical benefit
with PD-1 blockade, it is uncertain if only activated CD8+ cells
participated in the OS (50).
Two phase I, ongoing dose-escalation trials have been reported
with two IgG4 mAbs to PD-1. Lambrolizumab (MK-3475), which
has recently been designated by the FDA as a “breakthrough ther-
apy” drug to treat advanced melanoma (58), was used to treat 135
melanoma patients, who were evaluated for up to 70 weeks (59).
The confirmed response rate was 38% (44 of 117), irrespective of
prior ipilimumab treatment, and appeared dose-dependent. Biop-
sies of regressing lesions revealed densely infiltrated CD8+ T cells.
irAEs were 79% (107 of 135); 17 of the 107 had grade 3–4. Beside
skin and gastrointestinal problems, hypothyroidism was 8%. The
second phase I trial with nivolumab (BMS-936558) included 296
patients with melanoma, non-small cell lung cancer, prostate can-
cer, renal cell, or colorectal cancer. The first report in 2012 was
after ~1 year and the objective response averaged ~20–25% (55).
Grade 3–4 irAEs were observed in 14% (41 of 296), of which
11% were considered serious; 15 patients discontinued the study
and 3 deaths (1%) were attributed to pneumonitis. The spectrum
of irAEs was mostly similar to lambrolizumab therapy (59). But
with twice the number of patients, the variety of irAEs resembled
those seen with ipilimumab, albeit at lower overall percentages.
The spectrum was dose-dependent and included rash, pruritus,
and diarrhea (all at ~27%), with hyperthyroidism and hypothy-
roidism at 3–7% (55). An exception to the ipilimumab treatment
was the prominent pulmonary toxicities seen in 2–4% of patients
(55, 59). In addition to fatalities (55), the 2–4% in phase I trials
were of grade 3–4 (55, 59). A recent report about ongoing phase
II/III trials also listed pneumonitis as a notable side effect (60).
Whether it is autoimmune in origin is undetermined. An updated
analysis on 107 melanoma patients treated with nivolumab showed
40% OS at 3 years (61).
Another multicenter phase I trial enrolled 207 patients with-
out prior experience with CTLA-4, PD-1, or PD-L1 mAb, who
were given anti-PD-L1 (IgG4, BMS-936559) for a number of
solid tumors for up to 2 years (62). The durable response rate
was 6–17%. Treatment-related adverse events were noted in 61%
(126 of 207), and 39% (81 of 207) were considered irAEs; these
patients have a somewhat different spectrum and a lower per-
centage of irAEs compared to patients in the anti-PD-1 trials.
Because these investigators were also conducting the phase I trial
with nivolumab (55), their initial clinical impression was that anti-
PD-L1 blockade was inferior to anti-PD-1 in achieving objective
responses (62).
Interestingly, pneumonitis was not a noted side effect in the
anti-PD-L1 phase I trials (60, 62), but the 39% irAEs showed a
distinct autoimmune-related trend: rash, hypothyroidism, hepati-
tis, plus isolated cases of diabetes mellitus, and myasthenia
gravis, all mostly of grade 1–2 (62). PD-1 binds to both PD-
L1 (broad tissue distribution) and PD-L2 (limited primarily to
DCs) (63, 64). Since lung tissues express PD-L1 and contain
activated alveolar macrophages, it is possible that anti-PD-1 block-
ade removes the inhibitory signals that control tissue prolifera-
tion and cytokine production more so in the lung, resulting in
pneumonitis, whereas anti-PD-L1 blockade does not block the
immune-checkpoint between PD-1 and PD-L2. Another pos-
sibility is that, since self tolerance is maintained by the con-
tinuing interaction between PD-1 and PD-L1 to prevent TCR-
driven signaling (65), upon anti-PD-L1 blockade, autoreactive
T cells could become activated resulting in the autoimmune
syndromes reported.
COMBINING IMMUNE-CHECKPOINT INHIBITORS COULD
POTENTIATE AUTOIMMUNE SEQUELAE
There are multiple national clinical trials planned or ongoing with
ipilimumab plus chemo- or radio-therapeutic agents, cytokines
(e.g., GM-CSF, IL-2, IL-21), and other systemic immunomodula-
tors, most with the goal of stimulating the effector T cell arm with
some targeting dendritic and B cells also [see Ref. (51)]. Because
anti-CTLA inhibited Treg function and potentiated irAEs, the use
of low dose cyclophosphamide could further target nTregs (22,
45) and increase autoimmune sequelae, similar to Treg-depleting
anti-CD52 (1). In murine models of B16 melanoma tumors (66)
and CT26 colon and ID8-VEGF ovarian carcinomas (67), dual
blockade of CTLA-4 and PD-1 enhanced greater tumor rejection
than each alone. It should be noted that, unlike in clinical tri-
als, these tumors were manipulated to express GM-CSF, as was
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Table 1 | Function of CTLA-4 and PD-1 in the immune network and the impact of immune-checkpoint inhibitors anti-CTLA-4 and/or anti-PD-1 on
examples of tumor immunity and autoimmunity.
Functions Consequences Examples of anti-CTLA-4 and/or anti-PD-1 blockade on
Tumor immunity Autoimmunity
CTLA-4 upregulation on
APCs/peptide-stimulated Tregs
downmodulates B7-1/B7-2 on APCs
Suppresses priming of
naive/autoreactive T cells and
maintains peripheral tolerance
Morris et al. (15): EAT
Read et al. (70): colitis
Ansari et al. (72): type I
diabetes
CTLA-4 binding to B7-1 and B7-2 causes
reverse signaling through B7-1/B7-2
Activation of the tryptophan-
catabolizing enzyme indoleamine
2,3-dioxygenase inhibits T cell
priming and proliferation
Holmgaard et al. (68): melanoma Kwidzinski et al. (73): EAE
CTLA-4 signaling stimulates production
of cytokines TGF-β and/or IL-10 by Tregs
Inhibits function of APCs and T cells Liu et al. (75): colitis
CTLA-4 upregulation on activated T cells
binds to B7-1/B7-2 at high affinity
Negative feedback signaling inhibits
continued T cell proliferation
Leach et al. (69): colon carcinoma Oaks and Hallett (76): AITD
Hurwitz et al. (71): prostate
cancer
Hurwitz et al. (71): prostatitis
Choi et al. (77): CIA
Hurwitz et al. (78): EAE
Torino et al. (19): clinical
hypophysitis
Fc-dependent depletion of iTregs Simpson et al. (43) melanoma
CTLA-4 signaling alters motility and
inhibits T cell receptor-mediated “stop”
signal
Reduces efficiency of effector T cell
killing and APC interaction
Ruocco et al. (74): breast cancer
PD-1 signaling enhances Treg function Inhibits T cell priming and maintains
self tolerance
Ansari et al. (72): type I
diabetes
PD-1 signaling inhibits motility and T cell
receptor-mediated “stop” signal
Inhibits autoreactive T cell activation
and reduces effector T cell function
Holmgaard et al. (68): melanoma Fife et al. (65): type I diabetes
PD-1 upregulation on activated T cells Inhibits effector T cell function
(anergy or exhaustion)
Holmgaard et al. (68): melanoma Ansari et al. (72) type I
diabetesAhmadzadeh et al. (52):
melanoma patients
Wang et al. (53): melanoma
patients
Dual blockade Duraiswamy et al. (67): colon and
ovarian cancers
Curran et al. (66): melanoma
AITD, human autoimmune thyroid disease; APC, antigen-presenting cell; CIA, collagen-induced arthritis; EAE, experimental autoimmune encephalomyelitis; EAT,
experimental autoimmune thyroiditis; iTreg, induced regulatory T cell; Treg, regulatory T cell.
whole cell vaccination included in some experiments. The pres-
ence of GM-CSF could influence the expression pattern reported
for tumor-infiltrating lymphocytes (67). Table 1 lists the impor-
tant functions of CTLA-4 and PD-1 molecules in maintaining
homeostasis of the immune network, and provides examples of
the impact of anti-CTLA-4 and/or anti-PD-1 blockade on tumor
immunity and autoimmunity.
Since CTLA-4 blockade interferes with peripheral tolerance
induction/maintenance and affects primarily the early stages of
the immune response, and PD-1 blockade acts toward the late
stages at the tissue sites (79) and each can augment OS, dual
therapy could further enhance OS, provided that the irAEs are
not unreasonably additive. In melanoma patients, a phase I
trial combining ipilimumab and nivolumab has begun (80). The
need to test different regimens resulted in small patient sizes
of 33–53. While the spectrum of irAEs was essentially similar
to monotherapy, OS was higher at 24 weeks, based on previous
experience.
Longer follow-ups and additional trials will be necessary
to assess various parameters affecting irAEs: HLA genotype,
environmental and gender influences, and antigen specificities for
both Tregs and effector T cells. As seen in our EAT-anti-tumor
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models, subclinical autoimmune conditions (29), and mutual
stimulation arising from anti-tumor and autoimmune inflam-
mation also contribute to the overall response enhancing tumor
immunity and autoimmunity (24, 25). Importantly, there appears
to be different pathogenic pathways to autoimmune manifesta-
tions, with PD-1-deficiency favoring a pathogenic autoantibody
profile and CTLA-4 blockade favoring T cell-mediated organ
damage.
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